Literature DB >> 31113759

Plasma amyloid β 40/42 ratio predicts cerebral amyloidosis in cognitively normal individuals at risk for Alzheimer's disease.

Andrea Vergallo1, Lucile Mégret2, Simone Lista3, Enrica Cavedo3, Henrik Zetterberg4, Kaj Blennow5, Eugeen Vanmechelen6, Ann De Vos6, Marie-Odile Habert7, Marie-Claude Potier8, Bruno Dubois3, Christian Neri2, Harald Hampel9.   

Abstract

INTRODUCTION: Blood-based biomarkers of pathophysiological brain amyloid β (Aβ) accumulation, particularly for preclinical target and large-scale interventions, are warranted to effectively enrich Alzheimer's disease clinical trials and management.
METHODS: We investigated whether plasma concentrations of the Aβ1-40/Aβ1-42 ratio, assessed using the single-molecule array (Simoa) immunoassay, may predict brain Aβ positron emission tomography status in a large-scale longitudinal monocentric cohort (N = 276) of older individuals with subjective memory complaints. We performed a hypothesis-driven investigation followed by a no-a-priori hypothesis study using machine learning.
RESULTS: The receiver operating characteristic curve and machine learning showed a balanced accuracy of 76.5% and 81%, respectively, for the plasma Aβ1-40/Aβ1-42 ratio. The accuracy is not affected by the apolipoprotein E (APOE) ε4 allele, sex, or age. DISCUSSION: Our results encourage an independent validation cohort study to confirm the indication that the plasma Aβ1-40/Aβ1-42 ratio, assessed via Simoa, may improve future standard of care and clinical trial design.
Copyright © 2019 the Alzheimer's Association. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Alzheimer's disease; Amyloid PET; Classification and regression trees (CART); Machine learning; Plasma amyloid β; Simoa immunoassay; Subjective memory complainers

Mesh:

Substances:

Year:  2019        PMID: 31113759     DOI: 10.1016/j.jalz.2019.03.009

Source DB:  PubMed          Journal:  Alzheimers Dement        ISSN: 1552-5260            Impact factor:   21.566


  43 in total

Review 1.  Neurovascular dysfunction and vascular amyloid accumulation as early events in Alzheimer's disease.

Authors:  Ricardo Apátiga-Pérez; Luis O Soto-Rojas; B Berenice Campa-Córdoba; Nabil Itzi Luna-Viramontes; Elvis Cuevas; Ignacio Villanueva-Fierro; Miguel Angel Ontiveros-Torres; Marely Bravo-Muñoz; Paola Flores-Rodríguez; Linda Garcés-Ramirez; Fidel de la Cruz; José Francisco Montiel-Sosa; Mar Pacheco-Herrero; José Luna-Muñoz
Journal:  Metab Brain Dis       Date:  2021-08-18       Impact factor: 3.584

2.  Consideration of sex and gender in Alzheimer's disease and related disorders from a global perspective.

Authors:  Michelle M Mielke; Neelum T Aggarwal; Clara Vila-Castelar; Puja Agarwal; Eider M Arenaza-Urquijo; Benjamin Brett; Anna Brugulat-Serrat; Lyndsey E DuBose; Willem S Eikelboom; Jason Flatt; Nancy S Foldi; Sanne Franzen; Paola Gilsanz; Wei Li; Alison J McManus; Debora Melo van Lent; Sadaf Arefi Milani; C Elizabeth Shaaban; Shana D Stites; Erin Sundermann; Vidyani Suryadevara; Jean-Francoise Trani; Arlener D Turner; Jet M J Vonk; Yakeel T Quiroz; Ganesh M Babulal
Journal:  Alzheimers Dement       Date:  2022-04-08       Impact factor: 16.655

Review 3.  The path to biomarker-based diagnostic criteria for the spectrum of neurodegenerative diseases.

Authors:  Filippo Baldacci; Sonia Mazzucchi; Alessandra Della Vecchia; Linda Giampietri; Nicola Giannini; Maya Koronyo-Hamaoui; Roberto Ceravolo; Gabriele Siciliano; Ubaldo Bonuccelli; Fanny M Elahi; Andrea Vergallo; Simone Lista; Filippo Sean Giorgi; Harald Hampel
Journal:  Expert Rev Mol Diagn       Date:  2020-02-27       Impact factor: 5.225

4.  Associations of amyloid and neurodegeneration plasma biomarkers with comorbidities.

Authors:  Jeremy A Syrjanen; Michelle R Campbell; Alicia Algeciras-Schimnich; Prashanthi Vemuri; Jonathan Graff-Radford; Mary M Machulda; Guojun Bu; David S Knopman; Clifford R Jack; Ronald C Petersen; Michelle M Mielke
Journal:  Alzheimers Dement       Date:  2021-09-27       Impact factor: 16.655

5.  Blood Pressure Level Is Associated With Changes in Plasma Aβ1 -40 and Aβ1-42 Levels: A Cross-sectional Study Conducted in the Suburbs of Xi'an, China.

Authors:  Meilin She; Suhang Shang; Ningwei Hu; Chen Chen; Liangjun Dang; Ling Gao; Shan Wei; Kang Huo; Jingyi Wang; Jin Wang; Qiumin Qu
Journal:  Front Aging Neurosci       Date:  2021-06-04       Impact factor: 5.750

Review 6.  Neuroprotective Natural Products for Alzheimer's Disease.

Authors:  Xin Chen; Joshua Drew; Wren Berney; Wei Lei
Journal:  Cells       Date:  2021-05-25       Impact factor: 6.600

7.  Improvement in depressive symptoms after antiretroviral therapy initiation in people with HIV in Rakai, Uganda.

Authors:  Noeline Nakasujja; Alyssa C Vecchio; Deanna Saylor; Sarah Lofgren; Gertrude Nakigozi; David R Boulware; Alice Kisakye; James Batte; Richard Mayanja; Aggrey Anok; Steven J Reynolds; Thomas C Quinn; Carlos A Pardo; Anupama Kumar; Ronald H Gray; Maria J Wawer; Ned Sacktor; Leah H Rubin
Journal:  J Neurovirol       Date:  2021-07-31       Impact factor: 3.739

8.  Pathway Analysis for Plasma β-Amyloid, Tau and Neurofilament Light (ATN) in World Trade Center Responders at Midlife.

Authors:  Minos Kritikos; Sean A P Clouston; Erica D Diminich; Yael Deri; Xiaohua Yang; Melissa Carr; Sam Gandy; Mary Sano; Evelyn J Bromet; Benjamin J Luft
Journal:  Neurol Ther       Date:  2020-04-30

9.  Plasma neurofilament light associates with Alzheimer's disease metabolic decline in amyloid-positive individuals.

Authors:  Andréa L Benedet; Nicholas J Ashton; Tharick A Pascoal; Antoine Leuzy; Sulantha Mathotaarachchi; Min S Kang; Joseph Therriault; Melissa Savard; Mira Chamoun; Michael Schöll; Eduardo R Zimmer; Serge Gauthier; Aurélie Labbe; Henrik Zetterberg; Kaj Blennow; Pedro R Neto
Journal:  Alzheimers Dement (Amst)       Date:  2019-09-27

Review 10.  An Update on Blood-Based Markers of Alzheimer's Disease Using the SiMoA Platform.

Authors:  Danni Li; Michelle M Mielke
Journal:  Neurol Ther       Date:  2019-12-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.